| Drug Name: | Cantil |
| Manufacturer: | sanofi-aventis U.S. LLC |
| Other Info: | Rev. February 2006Manufactured for:sanofi-aventis U.S. LLCBridgewater, NJ 08807 |
| Clinical Trials: | |
CANTIL is indicated for use as adjunctive therapy in the treatment of peptic ulcer.
It has not been shown to be effective in contributing to the healing of peptic ulcer, decreasing the rate of recurrence, or preventing complications.In the presence of high environmental temperature, heat prostration (fever and heat stroke due to decreased sweating) can occur with use of CANTIL.Diarrhea may be an early symptom of incomplete intestinal obstruction especially in patients with ileostomy or colostomy.
In this instance, treatment with this drug would be inappropriate and possibly harmful.CANTIL may produce drowsiness or blurred vision.
The patient should be cautioned regarding activities requiring mental alertness such as operating a motor vehicle or other machinery or performing hazardous work while taking this drug.With overdosage, a curare-like action may occur i.e., neuromuscular blockage leading to muscular weakness and possible paralysis.It should be noted that the use of anticholinergic drugs in the treatment of gastric ulcer may produce a delay in gastric emptying time and may complicate such therapy (antral stasis).Psychosis has been reported in sensitive individuals given anticholinergic drugs.
CNS signs and symptoms include confusion, disorientation, short-term memory loss, hallucinations, dysarthria, ataxia, coma, euphoria, decreased anxiety, fatigue, insomnia, agitation and mannerisms and inappropriate affect.
These CNS signs and symptoms usually resolve within 12 to 24 hours after discontinuation of the medication.